Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab
- DOI
- 10.1016/j.ejca.2026.116750
- Published
- 2026-06
- Container
- European Journal of Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2026.116750,
title = {Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab},
author = {Andrea Casadei-Gardini and Terry Cheuk-Fung Yip and Alessandro Vitale and Federico Rossari and Toshifumi Tada and Goki Suda and Shigeo Shimose and Masatoshi Kudo and Jaekyung Cheon and Fabian Finkelmeier and Ho Yeong Lim and José Presa and Gianluca Masi and Changhoon Yoo and Sara Lonardi and Fabio Piscaglia and Takashi Kumada and Mario Scartozzi and Emiliano Tamburini and Francesco Giuseppe Foschi and Silvia Camera and Mara Persano and Alessandra Pia D’Agata and Michele Ferrara and Laura Passeri and Lorenza Rimassa and Margherita Rimini},
year = {2026},
journal = {European Journal of Cancer},
doi = {10.1016/j.ejca.2026.116750},
url = {https://doi.org/10.1016/j.ejca.2026.116750}
}RIS
TY - JOUR TI - Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab AU - Andrea Casadei-Gardini AU - Terry Cheuk-Fung Yip AU - Alessandro Vitale AU - Federico Rossari AU - Toshifumi Tada AU - Goki Suda AU - Shigeo Shimose AU - Masatoshi Kudo AU - Jaekyung Cheon AU - Fabian Finkelmeier AU - Ho Yeong Lim AU - José Presa AU - Gianluca Masi AU - Changhoon Yoo AU - Sara Lonardi AU - Fabio Piscaglia AU - Takashi Kumada AU - Mario Scartozzi AU - Emiliano Tamburini AU - Francesco Giuseppe Foschi AU - Silvia Camera AU - Mara Persano AU - Alessandra Pia D’Agata AU - Michele Ferrara AU - Laura Passeri AU - Lorenza Rimassa AU - Margherita Rimini PY - 2026 JO - European Journal of Cancer DO - 10.1016/j.ejca.2026.116750 UR - https://doi.org/10.1016/j.ejca.2026.116750 ER -
APA
Casadei-Gardini, A., Yip, T. C., Vitale, A., Rossari, F., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Lim, H. Y., Presa, J., Masi, G., Yoo, C., Lonardi, S., Piscaglia, F., Kumada, T., Scartozzi, M., Tamburini, E., Foschi, F. G., Camera, S., Persano, M., D’Agata, A. P., Ferrara, M., Passeri, L., Rimassa, L., & Rimini, M. (2026). Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116750
Source records
- crossref · retrieved 2026-09-26T16:46:39.159Z